Zydus to Acquire US-Based Assertio for $166.4 Million

Zydus to acquire US-based Assertio for $166.4 million

The tender offer is expected to commence within five business days following the date of the merger agreement. The transaction is expected to close in the financial year 2026-27, subject to satisfaction of all closing conditions.

Zydus to acquire Assertio in $166m deal

The offer was approved by Assertio’s Board of Directors, following a revised merger agreement process and is considered a “superior proposal” compared to the previous agreement with Garda The post Zydus to acquire Assertio in $166m deal appeared first on Pharmaceutical Business review.

Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash

All-Cash Tender Offer of $23.50 per share or $166.4 Million Offer Represents 30.6% Premium to Original Agreement with Garda Therapeutics AND 75.8% Premium to Unaffected PriceLAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced that, following an engagement process outlined under the revised merger agreement (the “Garda Merger Agreement”) with more... The post Assertio to Be Acqu…